Equity Overview
Price & Market Data
Price: $3.44
Daily Change: -$0.0893 / 2.60%
Range: $3.42 - $3.58
Market Cap: $191,937,504
Volume: 175,811
Performance Metrics
1 Week: 9.81%
1 Month: -4.67%
3 Months: -38.26%
6 Months: -43.94%
1 Year: -54.64%
YTD: -38.80%
Company Details
Employees: 172
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.